Diabetes - a Consequence of COVID-19 Infection.
COVID-19 infection
Diabetes mellitus type 1 and type 2
treatment
Journal
Materia socio-medica
ISSN: 1512-7680
Titre abrégé: Mater Sociomed
Pays: Bosnia and Herzegovina
ID NLM: 101281595
Informations de publication
Date de publication:
Mar 2022
Mar 2022
Historique:
received:
12
01
2022
accepted:
24
02
2022
entrez:
8
7
2022
pubmed:
9
7
2022
medline:
9
7
2022
Statut:
ppublish
Résumé
COVID-19 infection has shown many complications on all organ systems, including the pancreas, during the acute phase of infection and in the post covid period. Our goal was to compare the frequency of patients with type 1 and type 2 diabetes in the Outpatient Clinic "Srce Sarajeva", in the year before COVID-19, 2019, and during the COVID-19 infection, in 2020 and 2021. Our second goal was to monitor the incidence of diabetes after COVID-19 infection, the time of onset after the acute phase of the disease, and treatment options for individual patients depending on the value of glucose. The study was designed as a retrospective-prospective, with the consent of the Director of the Outpatient Clinic "Srce Sarajeva", and patient consent, in the period of January 2019 to December 2021. The study included 371 patients at the age between 18-70. In 2020 and 2021 there was a significant difference in the number of patient diagnosed with diabetes who came for examination, compared to 2019. The number of new-onset diagnosed patients with type 1 and type 2 diabetes was significantly higher in 2020 and 2021 compared to 2019. In 2020, out of five newly discovered type 1, 3 of them, with an average age of 23 (+/- 1-4), overcame COVID-19 infection, and diabetes was detected 3-4 weeks after overcoming COVID-19 infection. Of the 122 type 2 patients, 19 were newly diagnosed, 47 were of average age (+/- 2-6), 13 were COVID-19 infected, and diabetes was detected 4-6 weeks after infection. In 2021, out of 4 newly discovered type 1, 3 of them, with an average age of 22 (+/- 1-2), overcame COVID-19 infection, and diabetes was detected 2-3 weeks after overcoming COVID-19 infection. Of the 114 type 2 patients, 32 were newly diagnosed, 45 were of average age (+/- 2-6), 23 were COVID-19 infected, and diabetes was detected 6-8 weeks after infection. COVID-19 infection adversely affects the pancreatic tissue leading to the clinical picture of type 1 and type 2 diabetes, and all patients, especially those at high risk of developing the disease suggest blood sugar testing, 3-4 weeks after the acute phase of the disease, and earlier if they were on corticosteroid therapy.
Sections du résumé
Background
UNASSIGNED
COVID-19 infection has shown many complications on all organ systems, including the pancreas, during the acute phase of infection and in the post covid period.
Objective
UNASSIGNED
Our goal was to compare the frequency of patients with type 1 and type 2 diabetes in the Outpatient Clinic "Srce Sarajeva", in the year before COVID-19, 2019, and during the COVID-19 infection, in 2020 and 2021. Our second goal was to monitor the incidence of diabetes after COVID-19 infection, the time of onset after the acute phase of the disease, and treatment options for individual patients depending on the value of glucose.
Methods
UNASSIGNED
The study was designed as a retrospective-prospective, with the consent of the Director of the Outpatient Clinic "Srce Sarajeva", and patient consent, in the period of January 2019 to December 2021. The study included 371 patients at the age between 18-70.
Results
UNASSIGNED
In 2020 and 2021 there was a significant difference in the number of patient diagnosed with diabetes who came for examination, compared to 2019. The number of new-onset diagnosed patients with type 1 and type 2 diabetes was significantly higher in 2020 and 2021 compared to 2019. In 2020, out of five newly discovered type 1, 3 of them, with an average age of 23 (+/- 1-4), overcame COVID-19 infection, and diabetes was detected 3-4 weeks after overcoming COVID-19 infection. Of the 122 type 2 patients, 19 were newly diagnosed, 47 were of average age (+/- 2-6), 13 were COVID-19 infected, and diabetes was detected 4-6 weeks after infection. In 2021, out of 4 newly discovered type 1, 3 of them, with an average age of 22 (+/- 1-2), overcame COVID-19 infection, and diabetes was detected 2-3 weeks after overcoming COVID-19 infection. Of the 114 type 2 patients, 32 were newly diagnosed, 45 were of average age (+/- 2-6), 23 were COVID-19 infected, and diabetes was detected 6-8 weeks after infection.
Conclusion
UNASSIGNED
COVID-19 infection adversely affects the pancreatic tissue leading to the clinical picture of type 1 and type 2 diabetes, and all patients, especially those at high risk of developing the disease suggest blood sugar testing, 3-4 weeks after the acute phase of the disease, and earlier if they were on corticosteroid therapy.
Identifiants
pubmed: 35801074
doi: 10.5455/msm.2022.33.4-7
pii: MSM-34-4
pmc: PMC9229352
doi:
Types de publication
Journal Article
Langues
eng
Pagination
4-7Informations de copyright
© 2022 Azra Burekovic1,2, Zelija Velija Asimi3, Anida Divanovic4, Dzenana Halilovic1.
Déclaration de conflit d'intérêts
There are no conflicts of interest.
Références
Diabetes Care. 2020 Oct;43(10):2345-2348
pubmed: 32788285
N Engl J Med. 2021 Feb 25;384(8):693-704
pubmed: 32678530
Diabetes Res Clin Pract. 2020 Jun;164:108214
pubmed: 32416121
Int J Endocrinol Metab. 2021 Sep 15;19(4):e113220
pubmed: 35069750
World J Diabetes. 2021 Oct 15;12(10):1674-1692
pubmed: 34754370
Diabetes Care. 2020 Jul;43(7):1408-1415
pubmed: 32430456
Acta Diabetol. 2020 Oct;57(10):1265-1266
pubmed: 32653960
Lancet Diabetes Endocrinol. 2020 Oct;8(10):823-833
pubmed: 32798471
Diabetes Res Clin Pract. 2020 Jun;164:108166
pubmed: 32339533
Diabetes Obes Metab. 2020 Oct;22(10):1935-1941
pubmed: 32314455
N Engl J Med. 2020 Aug 20;383(8):789-790
pubmed: 32530585
Diabetes Obes Metab. 2020 Aug;22(8):1443-1454
pubmed: 32406594
J Diabetes Res. 2020 Aug 24;2020:3918723
pubmed: 33062712
JAMA. 2000 Apr 19;283(15):2008-12
pubmed: 10789670
Diabetes. 2021 Dec;70(12):2733-2744
pubmed: 34686519
Diabetes Metab Syndr. 2020 Nov-Dec;14(6):2211-2217
pubmed: 33395782
J Med Virol. 2022 Jun;94(6):2402-2413
pubmed: 35099819
Diabetes Res Clin Pract. 2020 Oct;168:108374
pubmed: 32805345
Int J Infect Dis. 2020 Feb;91:264-266
pubmed: 31953166
Diabetes Metab Syndr. 2020 Sep - Oct;14(5):1459-1462
pubmed: 32771918
Clin Obes. 2020 Dec;10(6):e12414
pubmed: 33079448
World J Virol. 2021 Sep 25;10(5):275-287
pubmed: 34631477